Literature DB >> 12926836

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.

L Bø1, C A Vedeler, H Nyland, B D Trapp, S J Mørk.   

Abstract

The present study examined the extent and distribution of lymphocyte infiltration in demyelinated lesions in the cerebral cortex of multiple sclerosis (MS) patients. Tissue sections from the brain of 10 MS patients and five patients without neurological disease were double labeled for myelin basic protein and the lymphocyte markers CD3, CD4, CD8, CD45RO, and CD20. The highest density of CD3-positive T cells was found in MS white matter lesions (40.4/10 high power fields (hpf)). Fewer T cells were detected in cortical lesions that extended through both white and gray matter (12.1/10 hpf; P < 0.001). The lowest number of T cells was detected in intracortical demyelinated lesions (1.1/10 hpf). This was equal to the lymphocyte density in nondemyelinated cerebral cortex within the same tissue block (1.1/10 hpf) or cerebral cortex in control brains (1.8/10 hpf). A similar distribution was found using the CD4, CD8, and CD45RO markers. CD20-positive B cells were scarce in all specimens examined. These data indicate that areas of intracortical demyelination in chronic MS are not associated with an increased number of lymphocytes, or an altered distribution of lymphocyte subsets, when compared with control areas in MS and control patients. This finding indicates that the extent of lymphocyte infiltration in MS lesions is dependent on lesion location.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12926836     DOI: 10.1191/1352458503ms917oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  130 in total

1.  Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.

Authors:  F Rinaldi; M Calabrese; D Seppi; M Puthenparampil; P Perini; P Gallo
Journal:  Neurol Sci       Date:  2011-01       Impact factor: 3.307

2.  In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Authors:  J Cohen-Adad; T Benner; D Greve; R P Kinkel; A Radding; B Fischl; B R Rosen; C Mainero
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

Review 3.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 4.  Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis.

Authors:  Ranjan Dutta
Journal:  Mult Scler       Date:  2013-09       Impact factor: 6.312

5.  Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter.

Authors:  Klaus Schmierer; Janet R Thavarajah; Shu F An; Sebastian Brandner; David H Miller; Daniel J Tozer
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

6.  Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.

Authors:  Jeroen J G Geurts; Lars Bö; Petra J W Pouwels; Jonas A Castelijns; Chris H Polman; Frederik Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

Review 7.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 8.  Grey matter damage in multiple sclerosis: a pathology perspective.

Authors:  Roel Klaver; Helga E De Vries; Geert J Schenk; Jeroen J G Geurts
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

9.  3D MPRAGE improves classification of cortical lesions in multiple sclerosis.

Authors:  F Nelson; A Poonawalla; P Hou; J S Wolinsky; P A Narayana
Journal:  Mult Scler       Date:  2008-11       Impact factor: 6.312

Review 10.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.